07:00 , Sep 3, 2012 |  BC Week In Review  |  Clinical News

ASC-101: Phase I/II started

America Stem Cell began an open-label, U.S. Phase I/II trial to evaluate ASC-101 in about 30 patients with hematologic malignancies who are undergoing dual umbilical cord blood transplantation. ASC-101 has Orphan Drug designation to treat...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Clinical News

ASC-101 regulatory update

FDA granted Orphan Drug designation for America Stem Cell's ASC-101 to treat myeloablation in patients receiving hematopoietic stem cell transplantation. The human recombinant enzyme is in preclinical testing for the indication. America Stem Cell Inc....
07:00 , Oct 19, 2009 |  BC Week In Review  |  Company News

America Stem Cell, Dara BioSciences deal

Dara is now eligible for up to $250,000 in milestones from America Stem Cell under an amended 2008 deal for America Stem Cell to conduct preclinical testing of Dara's dipeptidyl peptidase-4 (DPP-4) inhibitors to improve...
07:00 , Aug 10, 2009 |  BC Week In Review  |  Company News

America Stem Cell, Dara BioSciences deal

America Stem Cell will conduct preclinical testing of Dara's dipeptidyl peptidase-4 (DPP-4) inhibitors to improve the efficiency of hematopoietic stem cell (HSC) transplants. Further terms were not disclosed. America Stem Cell Inc. , Carlsbad, Calif....